IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, recently unveiled impressive preclinical data at the American Society of Cell & Gene Therapy (ASGCT) 26th Annual Meeting, highlighting the potential of their DeltEx Gamma-Delta T cells to target and destroy ovarian cancer cells. The findings demonstrate that even platinum-resistant and treatment-resistant ovarian cancer cell lines are no match for the power of these innovative gamma-delta T cells.
The exciting new findings from IN8bio show that a combination of gamma-delta T cells and chemotherapy can be a powerful way to target solid tumors, even outside the brain. William Ho, CEO and co-founder of IN8bio, is hopeful that this combination of DeltEx Gamma-Delta T cells could provide a promising new treatment for patients with ovarian cancer.
IN8bio’s DeltEx Drug Resistance Immunotherapy, or DeltEx DRI, utilizes revolutionary gamma-delta T cells to combat cancer. These advanced cells have been engineered to be resistant to the killing effects of chemotherapy, allowing them to remain active and be used in combination with other treatments to create a powerful tumor-eradicating effect.
Preclinical testing has shown that when temozolomide (TMZ) and poly ADP-ribose polymerase inhibitors (PARPi) are used together, it triggers a significant increase in the expression of NKG2D ligand (NKG2D-L) proteins on cancer cells.
As NKG2D-L render cancer cells more visible to the immune system, particularly gamma-delta T cells, they can better recognize and destroy even platinum-resistant and treatment-resistant ovarian cancer cells.
Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio, is highly optimistic about the far-reaching effects of this research and method. He lauded the data as a powerful demonstration of how gamma-delta T cell biology could potentially detect and eradicate cancer cells in a variety of difficult cancer cases. He enthusiastically looks forward to testing the applicability of INB-400 in ovarian cancer and other solid tumors.
About INB-400
INB-400 from IN8bio is the next breakthrough in autologous and allogeneic drug resistant immunotherapies (DRI). This revolutionary DeltEx technology is designed to resist chemotherapy, and allogeneic INB-400 will expand the usage of DRI gamma-delta T cells into solid tumors. This new “off-the-shelf” DeltEx DRI technology is a game changer for cancer treatment.
About IN8bio
IN8bio is on a mission to revolutionize cancer treatment. The clinical-stage biopharmaceutical company is harnessing the power of gamma-delta T cells, a specialized population of T cells that can detect and attack diseased tissue, to develop innovative cell therapies.
Through its DeltEx platform, IN8bio is utilizing allogeneic, autologous, iPSC and genetically modified approaches to create therapeutics that target solid and liquid tumors with accuracy and precision. With these cutting-edge treatments, IN8bio is striving to make a real difference in the fight against cancer.
IN8bio is pioneering the development of its revolutionary gamma-delta T cell product candidates, INB-200 and INB-100, with two groundbreaking Phase 1 clinical trials – one for newly diagnosed glioblastoma, and the other to treat leukemia patients undergoing hematopoietic stem cell transplantation.
Building on this success, IN8bio has now been granted IND clearance for INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed GBM, and is expanding its preclinical portfolio to explore further treatments for other hematological and solid tumor cancers.